Exhibit 107
Calculation of Filing Fee Table
Form S-8
(Form Type)
Idera Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered Securities
| Newly Registered Securities |
| Security Type | Security Class Title(1) | Fee Calculation or Carry Forward Rule | Amount Registered (1) | Proposed Maximum Offering Price Per Unit (2) | Proposed Maximum Aggregate Offering Price (2) | Fee Rate | Amount of Registration Fee | Carry Forward Form Type | Carry Forward File Number | Carry Forward Initial Effective Date | Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward |
Fees to be Paid | Equity | Common Stock, $0.001 par value | Rule 457(c) and Rule 457 (h) | 1,668,476 | $0.28 | $467,173 | $110.20 per $1,000,000.00 | $51.48 | - | - | - | - |
Fees Previously Paid | - | - | - | - | - | - | - | - | - | - | - | - |
| Carry Forward Securities |
Carry Forward Securities | - | - | - | - | - | - | - | - | - |
| Total Offering Amounts | | $467,173 | | $51.48 | | | | |
| Total Fees Previously Paid | | | | - | | | | |
| Total Fee Offsets | | | | $0.00 | | | | |
| Net Fee Due | | | | $51.48 | | | | |
(1) | Pursuant to Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement on Form S-8 shall also cover any additional shares of the registrant’s common stock, $0.001 par value (the “Common Stock”) which become issuable under the Aceragen, Inc. 2021 Stock Incentive Plan, as amended, by reason of any stock dividend, stock split, recapitalization, or any other similar transaction effected without the receipt of consideration which results in an increase in the number of outstanding shares of Common Stock. |
(2) | Estimated solely for the purpose of determining the registration fee pursuant to Rules 457(c) and 457(h) under the Securities Act, based on the average of the high and low prices of the Common Stock as reported on The Nasdaq Capital Market on December 19, 2022. |